Cargando…
Vasculitis: From Target Molecules to Novel Therapeutic Approaches
Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vesse...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301353/ https://www.ncbi.nlm.nih.gov/pubmed/34209028 http://dx.doi.org/10.3390/biomedicines9070757 |
_version_ | 1783726648861917184 |
---|---|
author | Chung, Sang-Wan |
author_facet | Chung, Sang-Wan |
author_sort | Chung, Sang-Wan |
collection | PubMed |
description | Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis. |
format | Online Article Text |
id | pubmed-8301353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83013532021-07-24 Vasculitis: From Target Molecules to Novel Therapeutic Approaches Chung, Sang-Wan Biomedicines Review Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis. MDPI 2021-06-30 /pmc/articles/PMC8301353/ /pubmed/34209028 http://dx.doi.org/10.3390/biomedicines9070757 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chung, Sang-Wan Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title | Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title_full | Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title_fullStr | Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title_full_unstemmed | Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title_short | Vasculitis: From Target Molecules to Novel Therapeutic Approaches |
title_sort | vasculitis: from target molecules to novel therapeutic approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301353/ https://www.ncbi.nlm.nih.gov/pubmed/34209028 http://dx.doi.org/10.3390/biomedicines9070757 |
work_keys_str_mv | AT chungsangwan vasculitisfromtargetmoleculestonoveltherapeuticapproaches |